@inproceedings{inproceedings, title  = {{DASL-HiCAP (ANZUP1801): The impact of darolutamide on standard therapy for localized very high-risk cancer of the prostate-A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk, clinically localized prostate cancer}},

 url = {{}},

 year = {{2020}},

 month = {{1}},

 author = {{Niazi T and Williams S and Davis ID and Stockler MR and Martin AJ and Hague W and Bracken K and Gorzeman M and Roncolato F and Yip S and Horvath L et al}},

 volume = {{38}},

 journal = {{JOURNAL OF CLINICAL ONCOLOGY}},

 issue = {{6}},

 note = {{Accessed on 2024/10/23}}}